Michael Egholm Standard Biotools Inc. (LAB) insider trading activity

Michael Egholm is President & CEO of STANDARD BIOTOOLS INC.. Currently has a direct ownership of 5.62 Million shares of LAB, which is worth approximately $6.97 Million. The most recent transaction as insider was on Nov 20, 2025, when has been sold 63,529 shares (Common Stock) at a price of $1.28 per share, resulting in proceeds of $81,317. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.62M

1.12% 3M change

281.21% 12M change

Total Value Held $6.97 Million

Michael Egholm Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 20 2025	SELL Payment of exercise price or tax liability	$81,317 $1.28 p/Share	63,529 Reduced 1.12%	5,617,837 Common Stock
Aug 20 2025	SELL Payment of exercise price or tax liability	$69,747 $1.27 p/Share	54,919 Reduced 0.96%	5,681,366 Common Stock
Aug 01 2025	BUY Grant, award, or other acquisition	-	3,000,000 Added 34.34%	5,736,285 Common Stock
May 28 2025	SELL Payment of exercise price or tax liability	$10,797 $1.09 p/Share	9,906 Reduced 0.36%	2,731,285 Common Stock
May 23 2025	SELL Open market or private sale	$5,144 $0.94 p/Share	5,473 Reduced 0.2%	2,741,191 Common Stock
May 22 2025	SELL Open market or private sale	$5,116 $1.0 p/Share	5,116 Reduced 0.19%	2,746,664 Common Stock
May 21 2025	SELL Open market or private sale	$4,860 $1.03 p/Share	4,719 Reduced 0.17%	2,751,780 Common Stock

May 20 2025	SELL Payment of exercise price or tax liability	$19,260 $1.05 p/Share	18,343 Reduced 0.66%	2,756,499 Common Stock
Apr 04 2025	SELL Payment of exercise price or tax liability	$61,713 $1.07 p/Share	57,676 Reduced 2.04%	2,774,842 Common Stock
Apr 04 2025	BUY Exercise of conversion of derivative security	-	196,512 Added 6.49%	2,832,518 Common Stock
Mar 21 2025	BUY Grant, award, or other acquisition	-	1,188,333 Added 31.07%	2,636,006 Common Stock
Feb 20 2025	SELL Payment of exercise price or tax liability	$43,133 $1.39 p/Share	31,031 Reduced 2.1%	1,447,673 Common Stock
Nov 20 2024	SELL Payment of exercise price or tax liability	$43,480 $1.51 p/Share	28,795 Reduced 1.92%	1,473,704 Common Stock
Aug 20 2024	SELL Payment of exercise price or tax liability	$55,567 $1.91 p/Share	29,093 Reduced 1.9%	1,502,499 Common Stock
May 20 2024	BUY Grant, award, or other acquisition	-	1,000,000 Added 39.5%	1,531,592 Common Stock
Apr 08 2024	SELL Payment of exercise price or tax liability	$277,948 $2.71 p/Share	102,564 Reduced 16.17%	531,592 Common Stock
Apr 05 2024	BUY Grant, award, or other acquisition	-	212,126 Added 25.07%	634,156 Common Stock
Apr 04 2024	BUY Exercise of conversion of derivative security	-	196,512 Added 31.77%	422,030 Common Stock
Jan 05 2024	BUY Grant, award, or other acquisition	-	9,006 Added 3.84%	225,518 Common Stock
Apr 04 2023	BUY Exercise of conversion of derivative security	-	196,512 Added 48.76%	206,512 Common Stock

Also insider at

ISO

IsoPlexis Corp Healthcare

Director

Michael Egholm

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LAB shares.

Notify only if

Value

Insider Trading

Get notified when an Standard Biotools Inc. insider buys or sells LAB shares.

Notify only if

Operation

Value

Type

News

Receive news related to STANDARD BIOTOOLS INC.

Track Activities on LAB

Account